Molecular mechanisms of high sensitivity of pathogenic fungi belonging to the genus Cryptococcus to the action of new potential anticancer and antifungal drug - 3-bromopyruvate (3-BP)

2015/19/N/NZ7/00956

Keywords

Descriptors

  • NZ7_14: Farmacja, farmakoterapia, farmakologia
  • NZ2_1: Genetyka molekularna
  • NZ6_7: Mykologia

Panel

NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution

Uniwersytet Wrocławski, Wydział Nauk Biologicznych

Voivodeship: dolnośląskie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr Katarzyna Anna Przywara

Number of co-investigators in the project: 2

Call

PRELUDIUM 10 – announced on 2015-09-15

Amount awarded
98 447 PLN
Project start date
2016-08-19
Project end date
2019-08-18
Project duration
36 months (the same as in the proposal)
Project status
Project settled

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Equipment purchased [PL]

  1. Komora laminarna (Polon - nr kat. KL-21). Cost: 18 819 PLN
  2. Microjet - Enbio - autoklaw. Cost: 5 228 PLN
  3. komputer - HP. Cost: 4 000 PLN

Information in the final report

Publication in academic press/journals (4)

  1. Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma

    Authors:
    Katarzyna Niedźwiecka, Mariusz Dyląg, Daria Augustyniak, Grażyna Majkowska-Skrobek, Magdalena Cal-Bąkowska, Young H. Ko, Peter L. Pedersen, Andre Goffeau, Stanisław Ułaszewski
    Academic press:
    Oncotarget (year: 2016, volume: 7, pages: 65614 - 65626), Publisher: Impact Journals
    Status:
    Published
    DOI:
    10.18632/oncotarget.11592 – link to the publication
  2. 3‐Bromopyruvate as a potent anti-cancer therapy in honor and memory of the late Professor André Goffeau

    Authors:
    Young H. Ko, Katarzyna Niedźwiecka, Margarida Casal, Peter L. Pedersen, Stanisław Ułaszewski
    Academic press:
    Yeast (year: 2018, volume: 2018, pages: 46033), Publisher: Wiley-Blackwell
    Status:
    Published
    DOI:
    10.1002/yea.3367 – link to the publication
  3. The Cryptococcus neoformans monocarboxylate transporter Jen4 is responsible for increased 3-bromopyruvate sensitivity.

    Authors:
    Katarzyna Niedźwiecka, David Ribas, Margarida Casal, Stanisław Ułaszewski
    Academic press:
    FEMS Yeast Research (year: 2019, volume: 19, pages: pii: foz029), Publisher: Oxford University Press
    Status:
    Published
    DOI:
    10.1093/femsyr/foz029 – link to the publication
  4. The HK2 Dependent Warburg Effect and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate

    Authors:
    Paweł Lis, Mariusz Dyląg, Katarzyna Niedźwiecka, Young H. Ko, Peter L. Pedersen, Andre Goffeau and Stanisław Ułaszewski
    Academic press:
    Molecules (year: 2016, volume: 21, pages: pii: E1730), Publisher: MDPI
    Status:
    Published
    DOI:
    10.3390/molecules21121730 – link to the publication

« New search

Graphic design and implementation: Jakub Piotrowski